*Oragenics Announces Spike Protein Cov-2 S-2P Created By The NIH And Licensed By The Company Demonstrates Protective Immunity In Immunized Mice Challenged With Mouse-adapted Sars-CoV-2 Virus(Benzinga) |
The future outlook for Soligenix (SNGX) stock is mixed with both potential upside and high risks. Here's an overview of what analysts ...
No comments:
Post a Comment